2000
DOI: 10.1002/1096-9071(200007)61:3<374::aid-jmv16>3.0.co;2-7
|View full text |Cite
|
Sign up to set email alerts
|

Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha

Abstract: Seroconversion of hepatitis B e antigen (HBeAg) is an important marker for resolution of active hepatitis B virus (HBV) infection and for a long-term positive response to treatment. Lamivudine, a nucleoside analogue, is the first effective oral treatment for chronic hepatitis B in patients with evidence of viral replication and liver disease. When appropriate patient groups are compared, treatment with lamivudine for 1 year leads to HBeAg seroconversion in a similar proportion of patients as a standard course … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
12
1

Year Published

2001
2001
2018
2018

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 24 publications
(13 citation statements)
references
References 34 publications
0
12
1
Order By: Relevance
“…It is known that seroconversion of HBeAg is a more important marker for resolution of active HBV infection and for a long‐term positive response to treatment 26 . In this study, no statistically significant difference was found in HBeAg seroconversion between the three therapy regimens.…”
Section: Discussioncontrasting
confidence: 54%
“…It is known that seroconversion of HBeAg is a more important marker for resolution of active HBV infection and for a long‐term positive response to treatment 26 . In this study, no statistically significant difference was found in HBeAg seroconversion between the three therapy regimens.…”
Section: Discussioncontrasting
confidence: 54%
“…The potential benefit of combining lamivudine and interferon has been reported by several studies 6,21 , 22 . According to the principles of antiviral therapy today, simultaneous dosing of both drugs is preferred, as rapid maximal virus suppression is thought to be essential to prevent drug resistance and enhance seroconversion 23 .…”
Section: Discussionmentioning
confidence: 99%
“…In HBe antigen (HBeAg)-positive chronic hepatitis, an established parameter for discontinuing therapy is HBeAg clearance and seroconversion to antiHBe, because it indicates a sustained response. Studies using lamivudine for 1 year demonstrated a 20% HBeAg negativity rate, and prolonging therapy to 3 years increased HBeAg loss to 40% (and even higher in patients with elevated alanine aminotransferase [ALT] levels) [2,[4][5][6]. Prolonging lamivudine therapy is associated with the emergence of variants in the highly conserved YMDD motif of the hepatitis B virus (HBV) polymerase [7,8].…”
mentioning
confidence: 99%